Norvegia -
norvegese -
Statens legemiddelverk
sporanox 100 mg
janssen-cilag as - itrakonazol - kapsel, hard - 100 mg
Norvegia -
norvegese -
Statens legemiddelverk
erythromycin panpharma 1 g
panpharma sa - erytromycinlaktobionat - pulver til infusjonsvæske, oppløsning - 1 g
Norvegia -
norvegese -
Statens legemiddelverk
nemona 49.5 % w/w
nouryon pulp and performance chemicals ab - hydrogenperoksid - konsentrat til behandlingsoppløsning til fisk - 49.5 % w/w
Norvegia -
norvegese -
Statens legemiddelverk
sporanox 100 mg
2care4 aps - itrakonazol - kapsel, hard - 100 mg
Unione Europea -
norvegese -
EMA (European Medicines Agency)
ketoconazole hra
hra pharma rare diseases - ketoconazole - cushing syndrome - antimykotika for systemisk bruk - ketokonazol hra er indisert for behandling av endogent cushings syndrom hos voksne og ungdom over 12 år.
Unione Europea -
norvegese -
EMA (European Medicines Agency)
hepcludex
gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirale midler til systemisk bruk - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.
Unione Europea -
norvegese -
EMA (European Medicines Agency)
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiske midler - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.
Unione Europea -
norvegese -
EMA (European Medicines Agency)
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.